
    
      The study objectives are to obtain the clinical experience of GR68755 1 mg QD in Japanese
      female subjects with severe d-IBS who have frequent bowel urgency and to obtain exploratory
      efficacy and safety data that can be used as reference for endpoints and dosage and
      administration of a next phase clinical study in Japan.

      After giving a written informed consent, subjects will undergo essential observation and
      examinations during the screening phase and subjects who meet the eligibility criteria will
      enter into the treatment phase. When subjects enter into the treatment phase, the subjects
      will administer GR68755 1 mg tablets QD in the morning every day for 28 days from the next
      day of receiving the investigational products.
    
  